亮細胞卵巢癌

Clear Cell Carcinoma of the Ovary

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 趙德讓(Tai-Jong Chao) ； 鄭文雄(Wen-Hsiung Cheng) ； 陳天惠(Tien-Hui Chen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2007年1期 (2007/04) Pp. 17-23

https://doi.org/10.7010/JGO.200704.0017

摘要

亮細胞卵巢癌是一種不多見但預後較差的卵巢上皮細胞癌，對以platinum爲主的化學治療效果較治療漿液性卵巢癌爲差。最近研究顯示，在platinum外，佐以paclitaxel的化學治療，效果則較好。另有報告顯示，以irinotecan合併cisplatin或mitomycin C，效果亦不錯。故選擇最佳的藥物組合是現階段對亮細胞卵巢癌的研究重點。

關鍵字

亮細胞卵巢癌 ； 化學治療 ； 鉑 ； 紫杉醇

並列摘要

Clear cell carcinoma of the ovary is uncommon, where they received attention due to the controversy in their poor prognosis and their distinctive clinical characteristics. Several studies show that patients with clear cell carcinoma of the ovary have a poor prognosis than does serous adenocarcinoma of the ovary. In the literature, the low response of clear cell carcinoma to conventional platinum-based chemotherapy is associated with poor prognosis. Some authors demonstrated a significantly increased median survival in ovarian clear cell carcinoma patients treated with paclitaxel-platinum/carboplatin based chemotherapy as compared to patients treated with platinum-based chemotherapy. Combination chemotherapy using irinotecan with cisplatin or mitomycin C has also been reported to be effective in early trials and case reports of patients with ovarian clear cell carcinoma. A new strategy for chemotherapy in ovarian clear cell carcinoma should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents.

並列關鍵字

Ovarian clear cell carcinoma ； Chemotherapy ； Platinum ； Paclitaxel